Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class ( GLP-2, Glutamine, and Growth Hormone), By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies), By Region and Competition, 2020-2030F

Market Overview

Global Short Bowel Syndrome Market was valued at USD 854.02 Million in 2024 and is expected to reach USD 1265.38 Million by 2030 with a CAGR of 6.73% during the forecast period. Short Bowel Syndrome  is a rare but debilitating medical condition that affects the digestive system, particularly the small intestine. Individuals with SBS have a reduced ability to absorb nutrients and fluids, leading to malnutrition, dehydration, and a host of other health complications. The global Short Bowel Syndrome market has witnessed significant advancements in recent years, offering hope to patients and healthcare providers alike.

Short Bowel Syndrome is primarily a result of surgical removal or damage to a significant portion of the small intestine. This can occur due to various factors, such as congenital defects, trauma, or diseases like Crohn's disease. According to a study, “Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study”, A recent study conducted in Japan on 673 newly diagnosed adults with Crohn's disease (CD) found that 63% exhibited an inflammatory phenotype, 60% had ileocolonic disease, and 49% had perianal lesions, indicating a notably high prevalence of perianal disease, most commonly in the form of abscesses or fistulas. In other studies across Asia, the rates of inflammatory disease were even higher, ranging from 66% to 81%.

The condition manifests through symptoms like diarrhea, malabsorption of nutrients, electrolyte imbalances, and weight loss. The global Short Bowel Syndrome market has experienced substantial growth in recent years. Several factors contribute to this, including an increased awareness of the condition, advances in medical technology, and a growing patient population. The prevalence of Short Bowel Syndrome has been on the rise, driving the demand for effective treatment options. This increase can be attributed to better diagnostic techniques and an aging population. Traditional treatment approaches for SBS focused on dietary management and parenteral nutrition. However, the market has seen a shift towards innovative therapies such as intestinal rehabilitation, microbiome-based treatments, and tissue engineering. Several pharmaceutical companies and research institutions are actively involved in the development of therapies and drugs for SBS. These players compete in a dynamic market, fostering innovation and new discoveries.

Kye Market Drivers

Increasing Incidence of Short Bowel Syndrome is Driving the Global Short Bowel Syndrome Market

The rise in Short Bowel Syndrome cases has led to an increased demand for treatments and therapies, which in turn is driving the growth of the global Short Bowel Syndrome market. The pharmaceutical industry has been investing in research and development to create medications that can help patients with SBS better absorb nutrients and manage their condition. These innovations are contributing to the growth of the market. Patients with SBS often require parenteral nutrition, which involves receiving essential nutrients intravenously. The demand for parenteral nutrition solutions and associated equipment has surged, leading to market expansion. In addition to parenteral nutrition, enteral nutrition plays a vital role in managing SBS. The market for specialized enteral formulas tailored to SBS patients is also growing. Minimally invasive surgical techniques and small bowel transplantation have improved outcomes for SBS patients. These advancements are contributing to the market's expansion. Increased awareness of Short Bowel Syndrome and the advocacy efforts of patient groups have led to more resources and research funding being allocated to the disease, further stimulating market growth.  Short bowel syndrome (SBS) in adults is characterized by having less than 180 to 200 cm of remaining small intestine, while the typical length of the small bowel ranges from 275 to 850 cm. The condition is relatively rare, with an estimated prevalence of 1 to 2 cases per 100,000 individuals annually.

The increasing incidence of Short Bowel Syndrome is a pressing healthcare concern that is driving the growth of the global Short Bowel Syndrome market. Factors such as medical advancements, improved survival rates for preterm infants, and the rising prevalence of inflammatory bowel diseases are contributing to this trend. The pharmaceutical, nutritional, and surgical sectors are all responding with innovations and treatments to improve the lives of those affected by SBS. As research and development continue to advance, there is hope for better management and improved outcomes for individuals living with this challenging condition.

Rising Investment in Research and Development is Driving the Global Short Bowel Syndrome Market

The global Short Bowel Syndrome market is experiencing a significant boost due to increased investment in R&D activities. This surge in funding is primarily driven by a growing understanding of the disease, advancements in medical technology, and a commitment to improving the quality of life for SBS patients. In August 2021, Takeda Pharmaceutical Company Limited introduced Gattex/Revestive, a subcutaneous injection designed for the treatment of short bowel syndrome, in Japan and obtained the green light from the Ministry of Health, Labor, and Welfare.

 Recent R&D initiatives have led to the development of innovative therapies that address the underlying causes of SBS. One such breakthrough is the development of tissue-engineered intestines, which have the potential to replace damaged or missing parts of the small intestine. These therapies hold promise for SBS patients who previously had limited treatment options. R&D efforts have also resulted in the creation of specialized nutritional formulations tailored to the unique needs of SBS patients. These formulations help patients meet their nutritional requirements and improve their overall health and well-being. This has led to an increased demand for such products in the market. Pharmaceutical companies are actively investing in the development of drugs that can enhance nutrient absorption in SBS patients. These drugs aim to reduce dependence on parenteral nutrition (intravenous feeding) and improve patients' ability to absorb nutrients orally, ultimately improving their quality of life. The surge in R&D investment has led to a rise in clinical trials focused on Short Bowel Syndrome. These trials not only help in evaluating the safety and efficacy of new treatments but also provide valuable data that can guide further research and development efforts.

The rising investment in research and development is transforming the landscape of the global Short Bowel Syndrome market. With innovative therapies, advanced nutritional support, and promising drug candidates in the pipeline, SBS patients can look forward to improved treatment options and a better quality of life. As R&D efforts continue to flourish, it is likely that the market will expand further, offering hope to those affected by this rare and challenging condition. Ultimately, the synergy between research, investment, and patient advocacy is driving the global Short Bowel Syndrome market toward a brighter future.

Download Free Sample Report

Key Market Challenges

Limited Patient Pool

A significant challenge for the Global Short Bowel Syndrome Market is the limited patient pool. SBS is classified as a rare disease, with a relatively small number of diagnosed cases globally. This low prevalence directly impacts the market’s size and limits the number of potential patients who require specialized treatments. The small patient base can be a deterrent for pharmaceutical companies, making it economically unfeasible to heavily invest in the research and development of new therapies. Pharmaceutical companies may hesitate to dedicate resources to the discovery of SBS treatments due to the limited return on investment, given that fewer patients require treatment. This challenge is compounded by the fact that many of the potential breakthroughs in SBS treatments may not receive the attention they deserve because of the limited market size. As a result, research in this area may lack the momentum needed to push forward innovative therapies and novel drug development, ultimately delaying the availability of new treatment options for SBS patients. Moreover, the fragmented nature of the patient pool can make it difficult to conduct large-scale clinical trials or gather sufficient data to demonstrate the effectiveness of new therapies. This creates a cycle of underinvestment and slower progress in improving SBS care.

High Treatment Costs

The treatment of Short Bowel Syndrome is associated with substantial financial burdens, making high treatment costs a significant challenge in the market. Patients with SBS often require continuous, long-term care, including parenteral nutrition (PN) to provide essential nutrients, as their intestines are unable to absorb them effectively. The cost of providing specialized medical care, such as hospital visits, monitoring, and ongoing treatments, adds up over time, placing considerable pressure on patients, healthcare systems, and insurance providers. Parenteral nutrition alone is a significant contributor to the high costs, as it involves specialized formulas and the use of intravenous feeding, often requiring hospitalization or home care support. In addition to ongoing nutritional care, surgery may be necessary for some SBS patients, which can include procedures like bowel transplants or other corrective surgeries to extend the remaining bowel length or improve its function. These surgeries come with their own associated costs, including preoperative evaluations, post-operative care, and the potential for complications or the need for further procedures. For both patients and insurance providers, the financial burden of SBS treatment can be overwhelming, which may lead to limited access to care, especially in low-income regions. For healthcare systems, the high cost of treatment represents a significant portion of healthcare spending, and without adequate financial support or cost-effective options, many patients may not receive the comprehensive care they need.

Nutritional Challenges

One of the core challenges for patients with Short Bowel Syndrome (SBS) is managing their nutrition and maintaining an optimal fluid balance. SBS results from the removal or dysfunction of a portion of the small intestine, which impairs nutrient absorption. This leads to widespread nutritional deficiencies and dehydration. Patients are often unable to absorb enough nutrients from food alone, requiring lifelong dietary management and specialized nutritional interventions. Nutritional deficiencies, particularly in vitamins, minerals, and electrolytes, are common, and without careful management, they can lead to serious health complications. As a result, patients may need to rely on supplements or parenteral nutrition (PN) for sustenance, which can be costly and complicated. Even with nutritional supplements, patients must adhere to strict, personalized dietary plans to minimize malabsorption and maintain adequate nutrient levels. Fluid balance is also a significant concern, as many SBS patients struggle with dehydration due to the reduced surface area available in the intestine for water absorption. The need for constant monitoring of fluid intake, electrolytes, and nutritional levels presents ongoing challenges for both patients and healthcare providers. In many cases, patients with SBS must frequently visit healthcare facilities for regular assessments, adjustments to their dietary plans, and management of complications such as electrolyte imbalances or dehydration. This complex nutritional management increases the burden on both patients and healthcare providers, underscoring the need for more effective therapies and support systems that can address the nutritional challenges associated with SBS.

Key Market Trends

Technological Advancements

Short Bowel Syndrome (SBS) is a rare, yet debilitating condition that affects individuals who have lost a significant portion of their small intestine, typically due to surgery or disease. This condition can lead to severe malabsorption of nutrients, causing patients to suffer from malnutrition and other related complications. Fortunately, recent advancements in medical technology have been driving significant growth in the global Short Bowel Syndrome market, offering hope to those afflicted with this condition. The global Short Bowel Syndrome market has been witnessing substantial growth in recent years. Several factors are contributing to this expansion, with technological advancements playing a pivotal role. Pharmaceutical companies have been actively developing new drugs and therapies to address the underlying causes and symptoms of SBS. These innovations aim to enhance nutrient absorption and improve the quality of life for SBS patients. In September 2022, Zealand Pharma A/S revealed encouraging outcomes from a phase 3 study of Glepaglutide aimed at addressing short bowel syndrome. Glepaglutide is a promising long-acting GLP-2 analog that could potentially outperform Teduglutide due to its unique benefits such as weekly administration and an extended duration of action. Advances in the development of specialized nutritional supplements tailored to the unique needs of SBS patients have improved the management of this condition. These supplements help individuals maintain a balanced diet and prevent malnutrition. Technological advancements in surgical techniques have made it possible to reconstruct the remaining intestine more effectively, allowing for better nutrient absorption. Minimally invasive surgical procedures reduce complications and recovery times. The rise of telemedicine has made it easier for SBS patients to access healthcare professionals and receive ongoing care. Remote monitoring and teleconsultations enable better disease management and early intervention. Mobile applications and wearable devices have emerged to help patients track their nutrition, manage symptoms, and communicate with their healthcare providers more effectively. These tools empower patients to take control of their health and engage in self-care. Ongoing research in gene therapy holds promise for potential long-term solutions to SBS. By modifying genes responsible for nutrient absorption, scientists aim to develop therapies that can restore intestinal function.

The global Short Bowel Syndrome market is undergoing a transformation driven by remarkable technological advancements. These innovations are improving the lives of SBS patients by offering more effective treatments, better nutritional support, and enhanced monitoring options. As pharmaceutical companies continue to invest in research and development, and medical technology continues to evolve, there is optimism that the future holds even more promising solutions for individuals suffering from Short Bowel Syndrome. This progress not only provides hope for those afflicted with the condition but also underscores the broader potential of technology to revolutionize healthcare across various medical domains.

Segmental Insights

Distribution Channel Insights

The Hospital Pharmacies segment is projected to experience rapid growth during the forecast period. Hospital pharmacies work closely with healthcare professionals to create customized medications and intravenous (IV) solutions for SBS patients. These medications are tailored to meet each patient's specific nutritional needs, helping to mitigate the symptoms and complications of the condition. SBS patients often require specialized nutrition support, such as Total Parenteral Nutrition (TPN) or Enteral Nutrition (EN). Hospital pharmacies are equipped to compound these nutritional formulas, ensuring that patients receive the appropriate nutrients and fluids to maintain their health. Hospital pharmacies have the infrastructure and expertise to stock and dispense specialized medications and therapies designed to treat SBS, such as teduglutide (Gattex) and loperamide. They ensure that patients have access to these crucial treatments without delays.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the global Short Bowel Syndrome market in 2024, holding the largest market share in terms of value. North America has long been at the forefront of medical research and development, and this holds true for SBS as well. The region boasts a robust infrastructure of research institutions, pharmaceutical companies, and healthcare facilities. Prominent universities and medical centers in the United States and Canada have actively engaged in clinical trials and research initiatives aimed at improving SBS management. The United States Food and Drug Administration (FDA) and Health Canada are renowned for their stringent yet efficient regulatory processes. These agencies play a pivotal role in ensuring the safety and efficacy of new SBS treatments. Companies operating in North America benefit from a transparent and well-defined regulatory pathway, which encourages innovation and investment in the SBS market. North America is home to some of the world's largest pharmaceutical companies, many of which have invested heavily in SBS research and development. These industry giants have the financial capacity and expertise to conduct extensive clinical trials and bring innovative treatments to market. Their involvement in the SBS market has driven significant advancements in treatment options.

Recent Developments

• Ironwood Pharmaceuticals, Inc. announced that it will present new data from studies on apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) during the 2024 Digestive Disease Week® (DDW) meeting, which will take place from May 18-21, 2024, in Washington, D.C. SBS-IF is a rare, chronic, debilitating condition where patients rely on parenteral support (PS) for nutrition, impacting an estimated 18,000 adults in the U.S., Europe, and Japan. The STARS Phase III trial, which assessed the safety and efficacy of once-weekly apraglutide in reducing PS dependency in SBS-IF patients, will feature its data as a late-breaker oral presentation at DDW 2024. Ironwood had previously announced topline results from the STARS Phase III trial in February 2024.
• Ironwood Pharmaceuticals, Inc. will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The data, derived from subgroup analyses of the primary endpoint of the pivotal Phase III STARS trial, will evaluate the treatment effect of apraglutide based on baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure (SBS-IF). The results, to be shared during an oral presentation on October 29, 2024 from 8:30 am to 8:40 am ET, demonstrate that apraglutide exhibited a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics such as the length of the remnant bowel. These findings build on the previously announced positive results from the Phase III pivotal trial.
• In April 2024, OMNY Health is excited to announce its collaboration with the leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) across the nation to introduce a new set of real-world data and evidence solutions for research. With over 5,000 GI providers now part of OMNY’s research network, which serves more than 10 million patients, the collaboration represents care delivered by over 380,000 providers and 75 million patients across the United States. This expansion into GI practice data marks a significant growth of OMNY's real-world data ecosystem, which partners with providers to facilitate compliant, large-scale research collaborations. OMNY works with health systems to provide insights into patient population characteristics, care delivery patterns, and treatment outcomes, all derived from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY’s solutions offer valuable data on disease severity, treatment rationale, treatment efficacy, and the influence of social determinants on treatment decisions and disease progression. By consolidating various EHRs into unified, de-identified research data products, OMNY enables researchers and providers to access comprehensive and detailed information to address biomedical and population health research questions.
• In December 2024, the FDA has rejected Zealand Pharma’s approval application for glepaglutide, a potential competitor to Takeda’s Gattex, for the treatment of short bowel syndrome (SBS), citing insufficient evidence. In its complete response letter, the agency advised the company to conduct another clinical trial to gather more data on the efficacy and safety of glepaglutide, as stated in a release from the Danish biotech on December 19. Zealand Pharma has indicated it will continue its discussions with the FDA to determine the path forward for U.S. approval, with plans to initiate a single Phase 3 trial next year. This additional trial is intended to provide further evidence for a resubmission to the FDA, as well as to support regulatory filings for glepaglutide in other regions outside the U.S.

Key Market Players

• Wellspect Healthcare (Dentsply Sirona Company)
• Emmaus Life Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• OPKO Health, Inc.
• OxThera AB
• Pfizer Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Short Bowel Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Short Bowel Syndrome Market, By Drug Class:

o   GLP-2

o   Glutamine

o   Growth Hormone

• Short Bowel Syndrome Market, By Distribution Channel:

o   Hospital Pharmacies

o   Online Sales

o   Retail Pharmacies

• Short Bowel Syndrome Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Short Bowel Syndrome Market.

Available Customizations:

Global Short Bowel Syndrome market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Short Bowel Syndrome Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]